LA JOLLA PHARMACEUTICAL CO

Form 4 March 03, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

OMB APPROVAL

burden hours per

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

response...

Section 16. Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

SECURITIES

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

5. Relationship of Reporting Person(s) to

Issuer

TANG KEVIN C

LA JOLLA PHARMACEUTICAL

2. Issuer Name and Ticker or Trading

(Check all applicable)

CO [LJPC]

(Last)

(Middle) 3. Date of Earliest Transaction

Symbol

_X__ Director Officer (give title X__ 10% Owner _ Other (specify

(Month/Day/Year)

03/01/2016

below)

4747 EXECUTIVE DRIVE, SUITE

(Street)

(First)

510

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

SAN DIEGO, CA 92121

(City)	(State)	(Zip) Tab	ole I - Non-	Derivative	Secu	rities Acquir	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	omr Dispos (Instr. 3,	ed of (4 and :	5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/01/2016		Code V P	Amount 20,000	(D)	Price \$ 16.1857	2,892,130	I (1)	By LP (1)
Common Stock	03/01/2016		P	20,000	A	\$ 16.1251	2,912,130	I (1)	By LP <u>(1)</u>
Common Stock	03/01/2016		P	15,972	A	\$ 16.942	2,928,102	I (1)	By LP <u>(1)</u>
Common Stock	03/02/2016		P	4,028	A	\$ 17.8565	2,932,130	I (1)	By LP (1)
Common Stock	03/02/2016		P	20,000	A	\$ 18.0764	2,952,130	I (1)	By LP <u>(1)</u>

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

Common Stock	03/02/2016	P	6,500	A	\$ 18.7669	2,958,630	I (1)	By LP (1)
Common Stock	03/03/2016	P	13,500	A	\$ 18.9096	2,972,130	I (1)	By LP (1)
Common Stock	03/03/2016	P	20,000	A	\$ 18.7244	2,992,130	I (1)	By LP (1)
Common Stock	03/03/2016	P	20,000	A	\$ 18.5453	3,012,130	I (1)	By LP (1)
Common Stock	03/03/2016	P	20,000	A	\$ 18.928	3,032,130	I (1)	By LP (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.		5.	6. Date Exerc	cisable and	7. Tit	le and	8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transa	ctio	nNumber	Expiration D	ate	Amou	unt of	Derivative
Security	or Exercise		any	Code		of	(Month/Day/	Year)	Unde	rlying	Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr.	8)	Derivative	e		Secur	rities	(Instr. 5)
	Derivative					Securities			(Instr	. 3 and 4)	
	Security					Acquired					
	·					(A) or					
						Disposed					
						of (D)					
						(Instr. 3,					
						4, and 5)					
						, ,					
										Amount	
							Date	Expiration		or	
							Exercisable Date	Title	itle Number		
							Lacicisable	Date		of	
				Code	V	(A) (D)				Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships					
. 0	Director	10% Owner	Officer	Other		
TANG KEVIN C 4747 EXECUTIVE DRIVE, SUITE 510 SAN DIEGO, CA 92121	X	X				
TANG CAPITAL PARTNERS LP 4747 EXECUTIVE DRIVE, SUITE 510 SAN DIEGO, CA 92121		X				
		X				

Reporting Owners 2

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

TANG CAPITAL MANAGEMENT LLC 4747 EXECUTIVE DRIVE, SUITE 510 SAN DIEGO, CA 92121

Signatures

/s/ Kevin C. Tang	03/03/2016
**Signature of Reporting Person	Date
/s/ Kevin C. Tang, Managing Member of Tang Capital Management, LLC, General Partner	03/03/2016
**Signature of Reporting Person	Date
/s/ Kevin C. Tang, Managing Member	03/03/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital
- (1) Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3